Home

Download

Statistics

Landscape

Help

Contact

	Dataset summary
	Drug summary
	Umap of single cell types and conditions (resistant and sensitive)
	Comparison of cell composition between the resistant and sensitive groups (This dataset does not contain this module)
	Comparison of intra-tumor heterogeneity (ITH) and epithelial-mesenchymal transition (EMT) scores of malignant cells between the resistant and sensitive groups
	Difference of cell-cell interactions between the resistant and sensitive groups (This dataset does not contain this module)
	Differentially expressed genes (DEGs) between the resistant and sensitive groups for each cell type
	Mechanism analysis of drug resistance-related DEGs for each cell type in the pre-treatment samples (This dataset does not contain this module)
	Mechanism analysis of drug resistance-related DEGs for each cell type in the post-treatment samples (This dataset does not contain this module)
	Mechanism analysis of drug resistance-related DEGs for each cell type in one patient or cell lines
	MicroRNAs (miRNAs) regulating drug resistance-related DEGs for Malignant cells
	Motifs and transcription factors (TFs) regulating drug resistance-related DEGs for each cell type
•	Differentially expressed genes act as transcription factors

Dataset: GSE140440

Dataset summary for GSE140440

Datast information	Dataset	GSE140440
	PMID	32513898
	Raw data ID/link	PRJNA589746
	Organism	Homo sapiens
	Source	DU145 and PC cell lines
	Tissue	Cell line
	Cancer type level1	Prostate cancer
	Cancer type level2	Prostate cancer
	Regimen	docetaxel
	Drug type	Chemotherapy
	Sample size	resistant 2, sensitive 2
	Cell number	284
	Extract protocol	SMART-seq v4
	Data processing	NA
	Public date	Public on Sep 01, 2020
	Description	This dataset has 1 cell line with a sensitive pre-treatment sample and a resistant post-treatment sample.

Top

Drug summary for GSE140440

Drug name	DrugBank ID	Drug type	Targets name	Targets uniprot ID
"Docetaxel"	DB01248	small molecule	TUBB1; MAP2; MAP4; MAPT; BCL2; NR1I2	Q9H4B7; P11137; P27816; P10636; P10415; O75469

Top

Umap of single cell types and conditions (resistant and sensitive)

Umap of cell types and conditions (resistant and sensitive). If this dataset has both pre-treatment and post-treatment samples, the cell types were annotated together. If this dataset is a cell line dataset, the UMAP of cell clusters and the cell ratio of drug-resistant and sensitive groups within each cluster will also be shown. (If the image exists, the user can click on it to enlarge it in a new window.)

Umap of cell types	Umap of conditions
Umap of cell clusters	Cell ratio of drug-resistant and sensitive groups within each cluster

Top

Comparison of cell composition between the resistant and sensitive groups

In the pre-treatment samples, the cell composition of the resistant and sensitive groups were compared.
* represents significant difference. (If the image exists, the user can click on it to enlarge it in a new window.)

In the post-treatment samples, the cell composition of the resistant and sensitive groups were compared.
* represents significant difference. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Comparison of ITH and EMT scores of malignant cells between the resistant and sensitive groups

Comparison of ITH (intra-tumoral heterogeneity) and EMT (epithelial-mesenchymal transition) scores of malignant cells between the resistant and sensitive groups. ITH represents intratumoral heterogeneity, EMT represents epithelial mesenchymal transition, pre represents pre-treatment, post represents post-treatment, post2 represents longer post-treatment. (If the image exists, the user can click on it to enlarge it in a new window.)

Comparison of ITH scores

Comparison of EMT scores

Top

Difference of cell-cell interactions between the resistant and sensitive groups

In the pre-treatment samples, the difference in cell-cell interactions between the resistant and sensitive groups was compared. The numbers indicate the count of cell-cell interactions that were either higher or lower in the resistant group compared to the sensitive group. The dot plots of significant ligand-receptor pairs in the resistant group and sensitive group are subsequently displayed. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

In the post-treatment samples, the difference in cell-cell interactions between the resistant and sensitive groups was compared. The numbers indicate the count of cell-cell interactions that were either higher or lower in the resistant group compared to the sensitive group. The dot plots of significant ligand-receptor pairs in the resistant group and sensitive group are subsequently displayed. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. The difference in cell-cell interactions between the resistant and sensitive groups was compared. The numbers indicate the count of cell-cell interactions that were either higher or lower in the resistant group compared to the sensitive group. The dot plots of significant ligand-receptor pairs in the resistant group and sensitive group are subsequently displayed. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Top

Differentially expressed genes (DEGs) between the resistant and sensitive groups for each cell type

In the pre-treatment samples, the differentially expressed genes (|avg_log2FC|>0.25 & p_val_adj<0.05) between the resistant and sensitive groups for each cell type.

In the post-treatment samples, the differentially expressed genes (|avg_log2FC|>0.25 & p_val_adj<0.05) between the resistant and sensitive groups for each cell type.

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. The following are differentially expressed genes (|avg_log2FC|>0.25 & p_val_adj<0.05) between the resistant and sensitive groups for each cell type.

Gene symbol	Gene id	avg_log2FC	p_val	p_val_adj	pct.1	pct.2	Cell type	Timepoint
RBX1	ENSG00000100387	0.250121	1.63e-08	4.55e-04	1	0.993	Malignant cells	NA
P3H2-AS1	ENSG00000225764	-0.260466	9.97e-07	2.79e-02	0.287	0.582	Malignant cells	NA
ADPGK-AS1	ENSG00000260898	-0.264132	5.25e-07	1.47e-02	0.16	0.433	Malignant cells	NA
DCLRE1CP1	ENSG00000237470	-0.269645	1.84e-07	5.15e-03	0.253	0.59	Malignant cells	NA
SMG1P4	ENSG00000185710	-0.270024	1.02e-07	2.86e-03	0.42	0.754	Malignant cells	NA
FTH1P4	ENSG00000242992	-0.270486	3.20e-09	8.96e-05	0.493	0.836	Malignant cells	NA
RP5-882O7.4	NA	-0.276765	1.04e-06	2.92e-02	0.507	0.784	Malignant cells	NA
XXbac-BPG181B23.7	NA	-0.278207	5.34e-08	1.49e-03	0.207	0.53	Malignant cells	NA
TUBB8P7	ENSG00000261812	-0.279094	5.66e-09	1.58e-04	0.387	0.746	Malignant cells	NA
RP11-253M7.1	NA	-0.280671	1.34e-09	3.74e-05	0.393	0.754	Malignant cells	NA
NPM1P22	ENSG00000227969	-0.282028	3.01e-07	8.42e-03	0.507	0.806	Malignant cells	NA
RP11-166B2.3	NA	-0.282524	3.66e-09	1.02e-04	0.287	0.634	Malignant cells	NA
FTH1P5	ENSG00000230204	-0.283528	2.41e-07	6.74e-03	0.52	0.799	Malignant cells	NA
RP11-872J21.5	NA	-0.284098	8.04e-09	2.25e-04	0.387	0.761	Malignant cells	NA
MORF4	ENSG00000234801	-0.284408	1.10e-06	3.07e-02	0.567	0.843	Malignant cells	NA
RPL7P6	ENSG00000227525	-0.288737	8.65e-08	2.42e-03	0.58	0.858	Malignant cells	NA
EIF4A1P10	ENSG00000229132	-0.289841	3.20e-08	8.94e-04	0.513	0.821	Malignant cells	NA
KCNQ5-IT1	NA	-0.291531	5.40e-07	1.51e-02	0.407	0.724	Malignant cells	NA
RP11-536P6.3	NA	-0.291531	8.97e-07	2.51e-02	0.54	0.821	Malignant cells	NA
ABT1P1	ENSG00000250496	-0.292365	1.11e-06	3.11e-02	0.527	0.799	Malignant cells	NA
FAM66B	ENSG00000280677	-0.295624	6.29e-08	1.76e-03	0.4	0.754	Malignant cells	NA
CTD-2313F11.3	NA	-0.295624	1.58e-06	4.42e-02	0.467	0.746	Malignant cells	NA
RP11-79L9.2	NA	-0.296354	5.70e-07	1.59e-02	0.487	0.776	Malignant cells	NA
PRDX1P1	ENSG00000214121	-0.297659	1.33e-06	3.72e-02	0.587	0.836	Malignant cells	NA
CTB-178M22.2	NA	-0.297796	3.70e-07	1.03e-02	0.393	0.709	Malignant cells	NA
RP11-173M1.5	NA	-0.299859	1.01e-06	2.82e-02	0.36	0.657	Malignant cells	NA
RP11-473I1.6	NA	-0.302552	6.95e-07	1.94e-02	0.487	0.754	Malignant cells	NA
RP11-713P17.3	NA	-0.303021	1.19e-06	3.33e-02	0.467	0.739	Malignant cells	NA
AC016700.5	NA	-0.306032	9.86e-07	2.76e-02	0.453	0.791	Malignant cells	NA
POTEF	ENSG00000196604	-0.306182	8.11e-07	2.27e-02	0.453	0.724	Malignant cells	NA
LRRC19	ENSG00000184434	-0.307846	2.03e-07	5.69e-03	0.493	0.746	Malignant cells	NA
ANXA8L1	ENSG00000264230	-0.309571	9.86e-08	2.76e-03	0.073	0.328	Malignant cells	NA
HSP90AA4P	ENSG00000281610	-0.311593	1.04e-07	2.90e-03	0.52	0.799	Malignant cells	NA
RP11-145E17.3	NA	-0.313351	1.74e-06	4.87e-02	0.373	0.649	Malignant cells	NA
RP11-329B9.1	NA	-0.313461	3.50e-07	9.78e-03	0.48	0.761	Malignant cells	NA
AC079776.3	NA	-0.313509	1.68e-06	4.70e-02	0.513	0.776	Malignant cells	NA
ITPK1-AS1	ENSG00000280802	-0.313705	3.18e-07	8.90e-03	0.387	0.687	Malignant cells	NA
RP11-152F13.10	NA	-0.314039	2.51e-07	7.01e-03	0.373	0.679	Malignant cells	NA
LY6G5C	ENSG00000231325	-0.31413	2.15e-07	6.02e-03	0.3	0.634	Malignant cells	NA
CTC-575D19.1	NA	-0.314733	1.84e-07	5.14e-03	0.247	0.552	Malignant cells	NA
PERM1	ENSG00000187642	-0.315307	1.00e-06	2.81e-02	0.407	0.724	Malignant cells	NA
RP11-156E8.1	NA	-0.317279	5.16e-07	1.44e-02	0.413	0.731	Malignant cells	NA
KRT18P17	ENSG00000213943	-0.318465	1.10e-06	3.07e-02	0.273	0.56	Malignant cells	NA
PRLHR	ENSG00000119973	-0.320271	1.15e-07	3.20e-03	0.367	0.687	Malignant cells	NA
RP11-326K13.3	NA	-0.320731	1.01e-06	2.83e-02	0.42	0.694	Malignant cells	NA
KCNH6	ENSG00000173826	-0.321067	7.58e-07	2.12e-02	0.473	0.769	Malignant cells	NA
ASB16	ENSG00000161664	-0.32251	5.21e-07	1.46e-02	0.433	0.709	Malignant cells	NA
NRG4	ENSG00000169752	-0.32385	1.47e-06	4.11e-02	0.387	0.679	Malignant cells	NA
RP11-447H19.1	NA	-0.323884	2.65e-08	7.40e-04	0.447	0.769	Malignant cells	NA
RP11-417O18.1	NA	-0.324193	6.47e-07	1.81e-02	0.473	0.761	Malignant cells	NA

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48

Top

Mechanism analysis of drug resistance-related DEGs for each cell type in the pre-treatment samples

Enrichment results for 5 known drug-resistant mechanisms in malignant cells and 1 known mechanism in TME cells.The "Signature" column represents the differentially expressed genes (DEGs) used for enrichment. The "Geneset" column represents the genes included in this mechanism. The "Overlap" column represents the number of genes in the "Geneset" that are enriched in the "Signature". The "Enriched Genes" column represents the genes in the "Geneset" that are enriched in the "Signature". (If the image exists, the user can click on it to enlarge it in a new window.)

Hallmark, KEGG and GOBP enrichment results for up-regulated genes in resistant group of pre-treatment samples. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Hallmark, KEGG and GOBP enrichment results for down-regulated genes in resistant group of pre-treatment samples. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window.Complete files can be downloaded from the download section.)

Top

Mechanism analysis of drug resistance-related DEGs for each cell type in the post-treatment samples

Enrichment results for 5 known drug resistance mechanisms in malignant cells and 1 known mechanism in TME cells.The "Signature" column represents the differentially expressed genes (DEGs) used for enrichment. The "Geneset" column represents the genes included in this mechanism. The "Overlap" column represents the number of genes in the "Geneset" that are enriched in the "Signature". The "Enriched Genes" column represents the genes in the "Geneset" that are enriched in the "Signature". (If the image exists, the user can click on it to enlarge it in a new window.)

Hallmark, KEGG and GOBP enrichment results for up-regulated genes in resistant group of post-treatment samples. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Hallmark, KEGG and GOBP enrichment results for down-regulated genes in resistant group of post-treatment samples. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Top

Mechanism analysis of drug resistance-related DEGs for each cell type in one patient or cell lines

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. Enrichment results for 5 known drug resistance mechanisms in malignant cells and 1 known mechanism in TME cells are shown here.The "Signature" column represents the differentially expressed genes (DEGs) used for enrichment. The "Geneset" column represents the genes included in this mechanism. The "Overlap" column represents the number of genes in the "Geneset" that are enriched in the "Signature". The "Enriched Genes" column represents the genes in the "Geneset" that are enriched in the "Signature". (If the image exists, the user can click on it to enlarge it in a new window.)

Enrichment results for 5 known drug resistance mechanisms in malignant cells

Mechnism	Pval	FDR	Signature	Geneset	Overlap	Background	Cell type	Enriched Genes
Unusual Activation of Pro-survival Pathway	9.80e-06	4.90e-05	2352	781	116	23467	Malignant cells	ADAM9,ANXA2,AREG,BCAT1,BIRC5,BRCA1,CCND2,CDCP1,CDK6,CDKN1A,DNMT1,FAM168A,GSK3B,HOXA13,IGF2BP1,JUN,MAP1LC3B,PARP1,SOCS2,SPRY2,TGFB1,TGFBR2,PBK,TYMS,VEGFA,AAMDC,ADAM22,SLC25A5,AGR2,ANXA1,BCL10,BTG1,BUB1,CBL,CCNA2,CCNB1,CDK1,CCND1,CCNG2,CD44,HSPD1,CLTC,CLU,CUL4B,CYLD,DUSP2,DHFR,E2F2,ENG,ERCC1,ETS1,EZH2,FANCD2,FGFR1,FUS,FZD1,GPER1,GRB2,GCLM,SLC16A3,HMGB2,HMGN5,HSPA8,EIF4A3,IL1B,CXCL8,ING4,ITGA5,ITGB1,KIF11,KLF4,LDHA,MXD4,NF2,MYBL2,MYO10,NOTCH3,PARP8,PDCD4,PLK1,PSMB5,PTPN12,RAD51,RAB22A,RAB27A,RICTOR,RRM1,RRM2,ROCK2,SDC2,SMC4,SNAI2,SRI,STARD10,TERT,TFAM,TMEM54,TOP2B,USP14,USP22,PLAU,ERCC4,YEATS4,PFKFB3,GNAS,HMGCS1,INSIG1,ITGB3,PRKCA,RCN1,SQLE,SPHK1,GGPS1,SAFB2,PDSS1,ACAT2
Irregularity in Drug Uptake and Drug Efflux	1.60e-01	3.60e-01	2352	37	6	23467	Malignant cells	ABCB1,ABCC2,ABCA10,ABCF2,ABCE1,ABCG1
Drug Inactivation by Structure Modification	2.80e-01	3.60e-01	2352	27	4	23467	Malignant cells	GSS,NME1,CMPK1,CYP51A1
Aberration of the Drug's Therapeutic Target	2.90e-01	3.60e-01	2352	90	11	23467	Malignant cells	BRCA1,CDK6,DHFR,EZH2,FGFR1,IL1B,JAK1,COMT,DPP4,MAOA,TOP2A
Epigenetic Alteration of DNA, RNA or Protein	1.00e+00	1.00e+00	2352	455	20	23467	Malignant cells	DNMT1,GSK3B,H2AFY,HOXA13,EIF4G2,SPRY2,TYMS,EZH2,CXCL8,PDCD4,SMC4,TIMP1,SNHG1,LINC00261,GDI2,CDK14,CDR1,MX1,LINC00707,RP11-166P13.3

Hallmark, KEGG and GOBP enrichment results for up-regulated genes in resistant group. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Up-regulated Hallmark	Up-regulated KEGG	Up-regulated GO BP

Hallmark, KEGG and GOBP enrichment results for down-regulated genes in resistant group. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Down-regulated Hallmark	Down-regulated KEGG	Down-regulated GO BP

Top

MicroRNAs (miRNAs) regulating drug resistance-related DEGs for malignant cells

In the pre-treatment samples, the miRNAs with a score greater than 80 that regulate the top10 abs(avg_log2FC) drug resistance-related DEGs for malignant cells are shown here. If the gene does not have any miRNAs with a score greater than 80, it will not be shown. Here only the names of miRNAs with a score greater than 90 are shown, but some names will not be shown because of too many overlaps. (Complete files containing all datasets and cell types can be downloaded from the download section.)

In the post-treatment samples, the miRNAs with a score greater than 80 that regulate the top10 abs(avg_log2FC) drug resistance-related DEGs for Malignant cells are shown here. If the gene does not have any miRNAs with a score greater than 80, it will not be shown. Here only the names of miRNAs with a score greater than 90 are shown, but some names will not be shown because of too many overlaps. (Complete files containing all datasets and cell types can be downloaded from the download section.)

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. The miRNAs with a score greater than 80 that regulate the top10 abs(avg_log2FC) drug resistance-related DEGs for Malignant cells are shown here. Here only the names of miRNAs with a score greater than 80 are shown, but some names will not be shown because of too many overlaps. If the gene does not have any miRNAs with a score greater than 90, it will not be shown. (Complete files containing all datasets and cell types can be downloaded from the download section.)

Regulating up-regulated DEGs in resistant group	Regulating down-regulated DEGs in resistant group

Top

Motifs and transcription factors (TFs) regulating drug resistance-related DEGs for each cell type

In the pre-treatment samples, the motifs and TFs that regulate drug resistance-related DEGs for each cell type are shown here. (Complete files can be downloaded from the download section.)

In the post-treatment samples, the motifs and TFs that regulate drug resistance-related DEGs for each cell type are shown here. (Complete files can be downloaded from the download section.)

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. Motifs and TFs that regulate drug resistance-related DEGs for each cell type are shown here. (Complete files can be downloaded from the download section.)

Motifs and TFs regulating up-regulated DEGs in resistant group

motif

NES

AUC

TF_highConf

Cell_type

Page: 1 2 3

Top

Differentially expressed genes act as transcription factors

This table shows the differentially expressed genes that act as transcription factors. (Complete files can be downloaded from the download section.)

TF	motif	Expression	Cell type	Timepoint
KLF13	metacluster_195.2	up	Malignant cells	NA
KLF9	metacluster_195.2	up	Malignant cells	NA
KLF4	metacluster_195.2	up	Malignant cells	NA
KLF7	metacluster_195.2	up	Malignant cells	NA
KLF13	hocomoco__KLF13_HUMAN.H11MO.0.D	up	Malignant cells	NA
KLF13	transfac_pro__M07461	up	Malignant cells	NA
KLF4	transfac_pro__M07461	up	Malignant cells	NA
KLF7	transfac_pro__M07461	up	Malignant cells	NA
KLF9	transfac_pro__M07461	up	Malignant cells	NA
KLF7	metacluster_170.2	up	Malignant cells	NA

Page: 1

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."